@article{oai:u-ryukyu.repo.nii.ac.jp:02011268,
 author = {Nakamura, Hideta and Miyagi, Kazuya and Otsuki, Mariko and Higure, Yuuri and Nishiyama, Naoya and Kinjo, Takeshi and Nakamatsu, Masashi and Haranaga, Shusaku and Tateyama, Masao and Fujita, Jiro},
 issue = {22},
 journal = {Internal Medicine},
 month = {Nov},
 note = {Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor., 論文},
 pages = {2945--2949},
 title = {Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19},
 volume = {59},
 year = {2020}
}